메뉴 건너뛰기




Volumn 16, Issue 1, 2012, Pages 203-209

Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment

Author keywords

Atrial fibrillation; Dabigatran; Dabigatran etexilate; Direct thrombin inhibitor; Intracranial hemorrhage; Ischemic stroke; Stroke

Indexed keywords

DABIGATRAN ETEXILATE; ECARIN; PROTAMINE SULFATE; WARFARIN;

EID: 84856807170     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-011-9591-y     Document Type: Review
Times cited : (23)

References (43)
  • 1
    • 36549087247 scopus 로고    scopus 로고
    • Status of the epidemiology of atrial fibrillation
    • DOI 10.1016/j.mcna.2007.09.002, PII S0025712507001307, Atrial Fibrillation
    • Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008; 92 (1): 17-40. (Pubitemid 350182405)
    • (2008) Medical Clinics of North America , vol.92 , Issue.1 , pp. 17-40
    • Kannel, W.B.1    Benjamin, E.J.2
  • 2
    • 0037221236 scopus 로고    scopus 로고
    • Atrial fibrillation is associated with severe acute ischemic stroke
    • DOI 10.1159/000068743
    • Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003; 22 (2): 118-23. (Pubitemid 36302428)
    • (2003) Neuroepidemiology , vol.22 , Issue.2 , pp. 118-123
    • Dulli, D.A.1    Stanko, H.2    Levine, R.L.3
  • 4
    • 0024543543 scopus 로고
    • Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study
    • Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989; 1 (8631): 175-9. (Pubitemid 19038801)
    • (1989) Lancet , vol.1 , Issue.8631 , pp. 175-179
    • Petersen, P.1    Godtfredsen, J.2    Andersen, B.3    Boysen, G.4    Andersen, E.D.5
  • 5
    • 0025914693 scopus 로고
    • Final results
    • Stroke Prevention in Atrial Fibrillation Study
    • Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84 (2): 527-539.
    • (1991) Circulation , vol.84 , Issue.2 , pp. 527-539
  • 6
    • 0025241137 scopus 로고
    • The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
    • The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators
    • The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323 (22): 1505-1511.
    • (1990) N Engl J Med , vol.323 , Issue.22 , pp. 1505-1511
  • 8
    • 0026478818 scopus 로고
    • Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators
    • Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators. N Engl J Med. 1992; 327 (20): 1406-12.
    • (1992) N Engl J Med , vol.327 , Issue.20 , pp. 1406-1412
    • Ezekowitz, M.D.1    Bridgers, S.L.2    James, K.E.3
  • 9
    • 0027505093 scopus 로고
    • Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
    • EAFT (European Atrial Fibrillation Trial) study group
    • Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) study group. Lancet 1993; 342 (8882): 1255-1262.
    • (1993) Lancet , vol.342 , Issue.8882 , pp. 1255-1262
  • 10
    • 34347394385 scopus 로고    scopus 로고
    • Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    • Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146 (12): 857-67. (Pubitemid 351650486)
    • (2007) Annals of Internal Medicine , vol.146 , Issue.12 , pp. 857-867
    • Hart, R.G.1    Pearce, L.A.2    Aguilar, M.I.3
  • 11
    • 0033527355 scopus 로고    scopus 로고
    • Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis
    • Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: ameta-analysis. Ann Intern Med. 1999; 131 (7): 492-501. (Pubitemid 29482392)
    • (1999) Annals of Internal Medicine , vol.131 , Issue.7 , pp. 492-501
    • Hart, R.G.1    Benavente, O.2    McBride, R.3    Pearce, L.A.4
  • 12
    • 77952220109 scopus 로고    scopus 로고
    • Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation
    • Siddiqui FM, Qureshi AI. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation. Expert Opin Pharmacother. 2010; 11 (8): 1403-11.
    • (2010) Expert Opin Pharmacother , vol.11 , Issue.8 , pp. 1403-1411
    • Siddiqui, F.M.1    Qureshi, A.I.2
  • 13
    • 71849117615 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    • Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361 (24): 2342-52.
    • (2009) N Engl J Med , vol.361 , Issue.24 , pp. 2342-2352
    • Schulman, S.1    Kearon, C.2    Kakkar, A.K.3
  • 14
    • 77957029781 scopus 로고    scopus 로고
    • Friedman, dabigatran etexilate: Pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty
    • Eriksson BI, Friedman RJ. Friedman, dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. ClinAppl Thromb Hemost. 2009; 15 (Suppl 1): 25S-31S.
    • (2009) ClinAppl Thromb Hemost , vol.15 , Issue.SUPPL. 1
    • Eriksson, B.I.1    Friedman, R.J.2
  • 15
    • 57649123692 scopus 로고    scopus 로고
    • Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
    • Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009; 24 (1): 1-9.
    • (2009) J Arthroplasty , vol.24 , Issue.1 , pp. 1-9
    • Ginsberg, J.S.1    Davidson, B.L.2    Comp, P.C.3
  • 19
    • 70349306707 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with atrial fibrillation
    • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361 (12): 1139-51.
    • (2009) N Engl J Med , vol.361 , Issue.12 , pp. 1139-1151
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 21
    • 77952167209 scopus 로고    scopus 로고
    • Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor
    • Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009; 15: 9S-16S.
    • (2009) Clin Appl Thromb Hemost , vol.15
    • Stangier, J.1    Clemens, A.2
  • 22
    • 1842633720 scopus 로고    scopus 로고
    • Prevention of venous thromboembolism following orthopaedic surgery: Clinical potential of direct thrombin inhibitors
    • DOI 10.2165/00003495-200464060-00002
    • Eriksson BI, Dahl OE. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs. 2004; 64 (6): 577-95. (Pubitemid 38482439)
    • (2004) Drugs , vol.64 , Issue.6 , pp. 577-595
    • Eriksson, B.I.1    Dahl, O.E.2
  • 25
    • 34447522035 scopus 로고    scopus 로고
    • In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate
    • DOI 10.1160/TH07-03-0183
    • Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In vitro profile and ex vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007; 98 (1): 155-62. (Pubitemid 47078782)
    • (2007) Thrombosis and Haemostasis , vol.98 , Issue.1 , pp. 155-162
    • Wienen, W.1    Stassen, J.-M.2    Priepke, H.3    Ries, U.J.4    Hauel, N.5
  • 26
    • 49149130353 scopus 로고    scopus 로고
    • Dabigatran etexilate
    • Sanford M, Plosker GL. Dabigatran etexilate. Drugs. 2008; 68 (12): 1699-709.
    • (2008) Drugs , vol.68 , Issue.12 , pp. 1699-1709
    • Sanford, M.1    Plosker, G.L.2
  • 27
    • 34548031359 scopus 로고    scopus 로고
    • The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    • DOI 10.1111/j.1365-2125.2007.02899.x
    • Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64 (3): 292-303. (Pubitemid 47283865)
    • (2007) British Journal of Clinical Pharmacology , vol.64 , Issue.3 , pp. 292-303
    • Stangier, J.1    Rathgen, K.2    Stahle, H.3    Gansser, D.4    Roth, W.5
  • 28
    • 37149005153 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
    • Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008; 47 (1): 47-59. (Pubitemid 350260888)
    • (2008) Clinical Pharmacokinetics , vol.47 , Issue.1 , pp. 47-59
    • Stangier, J.1    Stahle, H.2    Rathgen, K.3    Fuhr, R.4
  • 29
    • 77953168824 scopus 로고    scopus 로고
    • Dabigatran etexilate-anovel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
    • van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-anovel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103 (6): 1116-1127.
    • (2010) Thromb Haemost , vol.103 , Issue.6 , pp. 1116-1127
    • Van Ryn, J.1    Stangier, J.2    Haertter, S.3
  • 30
    • 77953161242 scopus 로고    scopus 로고
    • Laboratory monitoring of dabigatran during orthopedic surgery (abstract PP-WE-142)
    • Ulehlova J, Slavik L, Krcova V, et al. Laboratory monitoring of dabigatran during orthopedic surgery (abstract PP-WE-142). J Thromb Haemost. 2009; 7 (Suppl 2): 674.
    • (2009) J Thromb Haemost , vol.7 , Issue.SUPPL. 2 , pp. 674
    • Ulehlova, J.1    Slavik, L.2    Krcova, V.3
  • 31
    • 10844233894 scopus 로고    scopus 로고
    • The ecarin clotting time, a universal method to quantify direct thrombin inhibitors
    • DOI 10.1159/000081505
    • Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb. 2003; 33: 173-83. (Pubitemid 39664135)
    • (2003) Pathophysiology of Haemostasis and Thrombosis , vol.33 , Issue.4 , pp. 173-183
    • Nowak, G.1
  • 32
    • 84855225857 scopus 로고    scopus 로고
    • 1/13/2011
    • Advisory Committee Briefing Document. 2010 1/13/2011]; Available from: http: //www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf.
    • (2010) Advisory Committee Briefing Document
  • 33
    • 77957126877 scopus 로고    scopus 로고
    • Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran
    • De Smedt A, De Raedt S, Nieboer K, De Keyser J, Brouns R. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis. 2010; 30 (5): 533-534.
    • (2010) Cerebrovasc Dis , vol.30 , Issue.5 , pp. 533-534
    • De Smedt, A.1    De Raedt, S.2    Nieboer, K.3    De Keyser, J.4    Brouns, R.5
  • 35
    • 77952738550 scopus 로고    scopus 로고
    • Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor
    • Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost. 2010; 8 (4): 790-8.
    • (2010) J Thromb Haemost , vol.8 , Issue.4 , pp. 790-798
    • Ammollo, C.T.1    Semeraro, F.2    Incampo, F.3    Semeraro, N.4    Colucci, M.5
  • 37
    • 77954700046 scopus 로고    scopus 로고
    • Dabigatran and stroke thrombolysis
    • Dempfle CE, Hennerici MG. Dabigatran and stroke thrombolysis. Cerebrovasc Dis. 2010; 30 (2): 203-5.
    • (2010) Cerebrovasc Dis , vol.30 , Issue.2 , pp. 203-205
    • Dempfle, C.E.1    Hennerici, M.G.2
  • 38
    • 78349313002 scopus 로고    scopus 로고
    • Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE-LY trial
    • Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010; 9 (12): 1157-63.
    • (2010) Lancet Neurol , vol.9 , Issue.12 , pp. 1157-1163
    • Diener, H.C.1    Connolly, S.J.2    Ezekowitz, M.D.3
  • 40
    • 75549083726 scopus 로고    scopus 로고
    • Effect of recombinant activated Factor VII in critical bleeding: Clinical experience of asingle center
    • Sartori MT, Imbergamo S, Zanon E, et al. Effect of recombinant activated Factor VII in critical bleeding: clinical experience of asingle center. Clin Appl Thromb Hemost. 2009; 15: 628-35.
    • (2009) Clin Appl Thromb Hemost , vol.15 , pp. 628-635
    • Sartori, M.T.1    Imbergamo, S.2    Zanon, E.3
  • 41
    • 38349096220 scopus 로고    scopus 로고
    • Role of prothrombin complex concentrates in reversing warfarin anticoagulation: Areview of the literature
    • Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: areview of the literature. Am J Hematol. 2008; 83: 137-43.
    • (2008) Am J Hematol , vol.83 , pp. 137-143
    • Leissinger, C.A.1    Blatt, P.M.2    Hoots, W.K.3
  • 42
    • 70449555472 scopus 로고    scopus 로고
    • Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin
    • Fernlö f G, Sjö strö m BM, Lindell KM, et al. Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin. Blood Coagul Fibrinolysis. 2009; 20: 667-74.
    • (2009) Blood Coagul Fibrinolysis , vol.20 , pp. 667-674
    • Fernlöf, G.1    Sjöström, B.M.2    Lindell, K.M.3
  • 43
    • 77949421739 scopus 로고    scopus 로고
    • Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate
    • Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet. 2010; 49: 259-68.
    • (2010) Clin Pharmacokinet , vol.49 , pp. 259-268
    • Stangier, J.1    Rathgen, K.2    Stähle, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.